Asymmetric Septal Hypertrophy

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

1 week ago talkbio0Tagged annual, Antibody-Drug Conjugates, Asymmetric Septal Hypertrophy, CD64-targeting ADC, Leukemia, Myelocytic, Acute, Leukemia, Myelomonocytic, Chronic, meeting, Monocytic leukemia, OncoPrecision, Resistance (Psychotherapeutic)

OncoPrecision; ONC001; CD64-targeting ADC; monocytic leukemia; acute myeloid leukemia; ASH Annual Meeting; antibody-drug conjugate; CMML; therapy resistance

BostonGene to Showcase Transformative Impact of AI-Driven Profiling with Six Abstracts at the 67th American Society of Hematology Annual Meeting & Exposition

2 weeks ago talkbio0Tagged 67th, AI-driven, annual, Asymmetric Septal Hypertrophy, Biological Markers, BostonGene, Clinical Trials, Hematology (discipline), immune profiling, meeting, Molecular Profiling, Multiple Myeloma, Neoplasms, Precision - temporal, Stratification

BostonGene; AI-driven molecular profiling; hematology; 67th ASH Annual Meeting; immune profiling; multiple myeloma; patient stratification; clinical trials; biomarkers; precision oncology